KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Hunain Alam, Ming Tang, Mayinuer Maitituoheti, Shilpa S. Dhar, Manish Kumar, Chae Young Han, Chandrashekar R. Ambati, Samir B. Amin, Bingnan Gu, Tsai Yu Chen, Yu Hsi Lin, Jichao Chen, Florian L. Muller, Nagireddy Putluri, Elsa R. Flores, Francesco J. DeMayo, Laura Baseler, Kunal Rai, Min Gyu Lee

    Research output: Contribution to journalArticlepeer-review

    130 Scopus citations

    Abstract

    Histone methyltransferase KMT2D is frequently mutated in lung tumors, and Alam et al. identify KMT2D as a lung tumor suppressor. KMT2D deficiency induces aberrant metabolic reprogramming via super-enhancer impairment, conferring sensitivity to glycolytic inhibitors in lung cancer with KMT2D-inactivating mutations.

    Original languageEnglish (US)
    Pages (from-to)599-617.e7
    JournalCancer Cell
    Volume37
    Issue number4
    DOIs
    StatePublished - Apr 13 2020

    Keywords

    • KMT2D
    • epigenetic modifier
    • glycolysis
    • histone methylation
    • histone methyltransferase
    • inhibitor
    • lung cancer
    • metabolism
    • super-enhancer
    • tumor suppressor

    ASJC Scopus subject areas

    • Oncology
    • Cell Biology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer'. Together they form a unique fingerprint.

    Cite this